17
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      The E-Id Protein Axis Specifies Innate and Adaptive Lymphoid Cell Fate

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          SUMMARY

          Innate and adaptive lymphoid development is orchestrated by the activities of E-proteins and their antagonist Id-proteins, but how these factors regulate early T cell progenitor (ETP) and innate lymphoid cell (ILC) development remains unclear. Using multiple genetic strategies we demonstrated that E-proteins E2A and HEB acted in synergy in the thymus to establish T cell identity and to suppress the aberrant development of ILCs, including ILC2s and lymphoid tissue-inducer-like cells. E2A and HEB orchestrated T cell fate and suppressed the ILC transcription signature by activating the expression of genes associated with Notch receptors, T cell receptor (TCR) assembly, and TCR-mediated signaling. E2A and HEB acted in ETPs to establish and maintain a T cell-lineage specific enhancer repertoire, including regulatory elements associated with the Notch1 and Rag1/2 gene loci. Based on these and previous observations we propose that the E-Id protein axis specifies innate versus adaptive lymphoid cell fate.

          Graphical Abstract

          Related collections

          Author and article information

          Journal
          9432918
          8591
          Immunity
          Immunity
          Immunity
          1074-7613
          1097-4180
          18 May 2017
          16 May 2017
          16 May 2018
          : 46
          : 5
          : 818-834.e4
          Affiliations
          [1 ]Department of Immunology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan
          [2 ]Department of Molecular Biology, University of California, San Diego, La Jolla, CA 92093
          [3 ]Baylor Research Institute, Baylor Institute for Immunology Research, Dallas, TX 75246
          [4 ]Institute of Metabolomic Medicine and Center for Renal Translational Medicine, University of California, San Diego, La Jolla, CA92093
          [5 ]Department of Pathology and Tumor Biology, Kyoto University, Kyoto 606-8507, Japan
          [6 ]Division of Cellular Immunology, German Cancer Research Center, Im Neuenheimer Field 280, Heidelberg, Germany
          Author notes
          [7]

          These authors contributed equally to this work

          [8]

          Lead Contact

          Article
          PMC5512722 PMC5512722 5512722 nihpa873930
          10.1016/j.immuni.2017.04.022
          5512722
          28514688
          1c4e3932-e60a-41a5-9829-194ac48b004f
          History
          Categories
          Article

          Comments

          Comment on this article